Recent Press Releases

Allergan Comments on Order Regarding Permanent Injunction against Merz Pharmaceuticals and Merz Aesthetics  

Allergan's BOTOX^® (Botulinum Toxin Type A) Receives UK Authorisation for Urinary Leakage in Patients with Multiple Sclerosis or Spinal Cord Injury  

Allergan Opens New Research and Development Center in Bridgewater, New Jersey  

Allergan and Molecular Partners Enter into Exclusive Alliance  

Allergan Reports Second Quarter 2012 Operating Results  

Allergan Announces Quarterly Conference Call  

BOTOX^® (Allergan's botulinum toxin type A) given Final Guidance from the National Institute for Health and Clinical Excellence (NICE) for the prevention of chronic migraine in patients who have failed previous treatme  

Scottish Medicines Consortium accepts OZURDEX^® (dexamethasone 700mcg intravitreal implant) for use within NHS Scotland  

BOTOX Allergan's botulinum toxin type A recommended  

Allergan Launches First EU Public Awareness & Education Campaign on the Importance of Quality in Medical Aesthetics  

Allergan Reports First Quarter 2012 Operating Results  

BOTOX® Cosmetic (onabotulinumtoxinA) Celebrates 10-Year Anniversary of U.S. Food and Drug Administration Approval  

Allergan Announces Quarterly Conference Call  

Allergan Announces Positive Top-Line Results from Phase III BOTOX® Overactive Bladder Program  

U.S. Federal Court Finds in Favor of Allergan, Inc. and Issues Permanent Injunction against Merz Pharmaceuticals and Merz Aesthetics  

Allergan Announces Research & Development Technology Review  

Allergan Reports Fourth Quarter 2011 Operating Results  

Allergan Announces Quarterly Conference Call  

Allergan Reassures Patients and Surgeons of the Quality and Safety of Its Breast Implant Devices Sold and Distributed Worldwide  

Health Canada approves BOTOX® as prophylactic treatment for chronic migraine